WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H333073
CAS#: 722533-56-4 (free base)
Description: Elacestrant, also known as RAD1901, is an orally available, selective estrogen receptor degrader (SERD) and selective estrogen receptor modulator (SERM), with potential antineoplastic and estrogen-like activities. Upon oral administration of higher doses of RAD1901, this agent acts as a SERD, which binds to the estrogen receptor (ER) and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells. At lower doses of this agent, RAD1901 acts as a SERM and has estrogen-like effects in certain tissues, which can both reduce hot flashes and protect against bone loss. In addition, RAD1901 is able to cross the blood-brain barrier (BBB).
Hodoodo Cat#: H333073
Name: Elacestrant free base
CAS#: 722533-56-4 (free base)
Chemical Formula: C30H38N2O2
Exact Mass: 458.29
Molecular Weight: 458.646
Elemental Analysis: C, 78.56; H, 8.35; N, 6.11; O, 6.98
Related CAS #: 1349723-93-8 (HCl) 722533-56-4 (free base)
Synonym: RAD1901; RAD-1901; RAD 1901; RAD1901; Elacestrant; Elacestrant free base
IUPAC/Chemical Name: (R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol
InChi Key: SIFNOOUKXBRGGB-AREMUKBSSA-N
InChi Code: InChI=1S/C30H38N2O2/c1-4-31-17-16-22-6-8-23(9-7-22)21-32(5-2)30-20-28(34-3)14-15-29(30)26-11-10-25-19-27(33)13-12-24(25)18-26/h6-9,12-15,19-20,26,31,33H,4-5,10-11,16-18,21H2,1-3H3/t26-/m1/s1
SMILES Code: OC1=CC=C2C[C@H](C3=CC=C(OC)C=C3N(CC)CC4=CC=C(CCNCC)C=C4)CCC2=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 458.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Novel SERD Has PFS Edge against Breast Cancer. Cancer Discov. 2021 Dec 14. doi: 10.1158/2159-8290.CD-NB2021-0406. Epub ahead of print. PMID: 34906954.
2: Olivier T, Prasad V. Elacestrant in metastatic breast cancer: Is the "standard of care" meeting standard requirements? Transl Oncol. 2022 Jan;15(1):101273. doi: 10.1016/j.tranon.2021.101273. Epub 2021 Nov 16. PMID: 34798371; PMCID: PMC8605291.
3: Chen YC, Yu J, Metcalfe C, De Bruyn T, Gelzleichter T, Malhi V, Perez-Moreno PD, Wang X. Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer. Expert Opin Investig Drugs. 2021 Oct 25:1-15. doi: 10.1080/13543784.2021.1983542. Epub ahead of print. PMID: 34694932.
4: Early Signs of Response to Elacestrant Seen in ER+ HER2- Breast Cancer. Cancer Discov. 2021 May;11(5):OF13. doi: 10.1158/2159-8290.CD-RW2021-021. Epub 2021 Feb 15. PMID: 33589422.
5: Dehdashti F, Wu N, Ma CX, Naughton MJ, Katzenellenbogen JA, Siegel BA. Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy. Nat Commun. 2021 Feb 2;12(1):733. doi: 10.1038/s41467-020-20814-9. PMID: 33531464; PMCID: PMC7854611.
6: Bardia A, Kaklamani V, Wilks S, Weise A, Richards D, Harb W, Osborne C, Wesolowski R, Karuturi M, Conkling P, Bagley RG, Wang Y, Conlan MG, Kabos P. Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer. J Clin Oncol. 2021 Apr 20;39(12):1360-1370. doi: 10.1200/JCO.20.02272. Epub 2021 Jan 29. PMID: 33513026; PMCID: PMC8078341.
7: Jager A, de Vries EGE, der Houven van Oordt CWM, Neven P, Venema CM, Glaudemans AWJM, Wang Y, Bagley RG, Conlan MG, Aftimos P. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging. Breast Cancer Res. 2020 Sep 11;22(1):97. doi: 10.1186/s13058-020-01333-3. PMID: 32912274; PMCID: PMC7488419.
8: Stravodimou A, Voutsadakis IA. The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors. Anticancer Res. 2020 Sep;40(9):4829-4841. doi: 10.21873/anticanres.14486. PMID: 32878771.
9: Conlan MG, de Vries EFJ, Glaudemans A, Wang Y, Troy S. Correction to: Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women. Eur J Drug Metab Pharmacokinet. 2020 Oct;45(5):691-692. doi: 10.1007/s13318-020-00638-0. Erratum for: Eur J Drug Metab Pharmacokinet. 2020 Oct;45(5):675-689. PMID: 32862369; PMCID: PMC7511466.
10: Conlan MG, de Vries EFJ, Glaudemans A, Wang Y, Troy S. Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women. Eur J Drug Metab Pharmacokinet. 2020 Oct;45(5):675-689. doi: 10.1007/s13318-020-00635-3. Erratum in: Eur J Drug Metab Pharmacokinet. 2020 Aug 30;: PMID: 32661909; PMCID: PMC7511284.
11: Patel HK, Tao N, Lee KM, Huerta M, Arlt H, Mullarkey T, Troy S, Arteaga CL, Bihani T. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors. Breast Cancer Res. 2019 Dec 18;21(1):146. doi: 10.1186/s13058-019-1230-0. PMID: 31852484; PMCID: PMC6921513.
12: Chinnasamy K, Saravanan M, Poomani K. Investigation of binding mechanism and downregulation of elacestrant for wild and L536S mutant estrogen receptor-α through molecular dynamics simulation and binding free energy analysis. J Comput Chem. 2020 Jan 15;41(2):97-109. doi: 10.1002/jcc.26076. Epub 2019 Oct 10. PMID: 31602686.
13: Bardia A, Aftimos P, Bihani T, Anderson-Villaluz AT, Jung J, Conlan MG, Kaklamani VG. EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. Future Oncol. 2019 Oct;15(28):3209-3218. doi: 10.2217/fon-2019-0370. Epub 2019 Aug 20. PMID: 31426673.
14: Shah N, Mohammad AS, Saralkar P, Sprowls SA, Vickers SD, John D, Tallman RM, Lucke-Wold BP, Jarrell KE, Pinti M, Nolan RL, Lockman PR. Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases. Pharmacol Res. 2018 Jun;132:47-68. doi: 10.1016/j.phrs.2018.03.021. Epub 2018 Mar 28. PMID: 29604436; PMCID: PMC5997530.
15: Bihani T, Patel HK, Arlt H, Tao N, Jiang H, Brown JL, Purandare DM, Hattersley G, Garner F. Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models. Clin Cancer Res. 2017 Aug 15;23(16):4793-4804. doi: 10.1158/1078-0432.CCR-16-2561. Epub 2017 May 4. PMID: 28473534.
